Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atea Pharmaceuticals, Inc. (AVIR)

Atea signs up to $200 million Hercules term loan, $65 million drawn at closing

Neutral Impact 4 of 5 financing

Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.

Key points

  • Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
  • Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
  • Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
  • Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR

The filing

CompanyAtea Pharmaceuticals, Inc. (AVIR)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:30 AM ET
Accession number0001193125-26-452659

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:35 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.